Less than a tenth of people that would benefit from obesity jabs like Wegovy can access them, caution the global health agency as it publishes its first guidance on the medications.
Considering over a billion individuals worldwide currently obese, it is advocating for increased and just access to these injectable treatments.
Based on estimates, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"The latest guidance acknowledges that excess weight is a long-term condition that can be treated with thorough and lifelong support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are major hurdles to broad access to the treatments that can assist patients in reducing significant body mass, explains the body.
Skinny Jab Shortage
Despite the current most optimistic outlook, the manufacturing of GLP-1 therapies might only reach about 100 million people – fewer than 10% of those who need them, as stated by the WHO.
The guideline urges nations and manufacturers to expand access, by measures such as patent sharing.
The intellectual property rights on the active ingredient – the primary ingredient of a leading brand – is due to expire in a number of nations in 2026.
The Way Weight-Loss Injections Work
GLP-1 drugs imitate a natural hormone to delay gastric emptying, suppress the appetite and increase satiety so individuals consume fewer calories.
Patients commonly start to lose weight in the initial weeks of commencing the once-weekly jabs.
Research suggests users may see weight return after a year of halting the treatment, because their typical food cravings come back.
To be carrying excess weight raises your risk for experiencing health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Excess weight concerns people in all nations and was linked to 3.7 million deaths worldwide in 2024, according to the WHO.
